Results 181 to 190 of about 66,826 (280)

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In Chinese patients with moderate to severe plaque psoriasis, bimekizumab treatment was well tolerated and led to significantly higher clinical response rates versus placebo, including complete skin clearance. These findings were consistent with global studies and suggest that bimekizumab is an effective treatment option for Chinese people living with ...
Lin Cai, Xiao‐Yong Man, Jinyan Wang, Aihua Wei, Ying Chen, Delphine Deherder, Jun Gao, Bengt Hoepken, Weiwei Sun, Tingting Lei, Jianzhong Zhang, the BE SHINING Study Group   +11 more
wiley   +1 more source

Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology. [PDF]

Arthritis Res Ther
Burlo F, Pastore S, Stocco G, Zuanna PD, Curci D, Mizuno T, Irie K, Taddio A, Tommasini A.   +8 more
europepmc   +1 more source

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber, Knut Schäkel, Alexander Enk, Julia K. Winkler   +3 more
wiley   +1 more source

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos, Evangelos J. Giamarellos‐Bourboulis, Kelsey R. van Straalen, Antonio Martorell, Brian Kirby, Afsaneh Alavi, Koremasa Hayama, Saakshi Khattri, Wayne Gulliver, Christopher J. Sayed, Leah Davis, Robert L. Rolleri, Christina Crater, Ingrid Pansar, Jérémy Lambert, Christos C. Zouboulis   +15 more
wiley   +1 more source

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol. [PDF]

BMJ Open
Fisher BA, Rowe A, Hodson C, Wilkhu M, Williams E, Turner E, Allard A, Blake T, Bombardieri M, Cope AP, Dubey S, Mankia K, Malley T, Moore O, Payne M, Plummer R, Tilby M, Tillett T, Wong E, Wu Y, Filer A, Pratt A, Pallan L, Homer V.   +23 more
europepmc   +1 more source

Effective Management of Recalcitrant Hailey–Hailey Disease With Risankizumab

International Journal of Dermatology, EarlyView.
Joy Justice, Adriana Della Porta, Eva Niklinska, Jami L. Miller   +3 more
wiley   +1 more source

Mapping malignant T‐cell states and immune circuits in Sézary syndrome by single‐cell analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Peripheral blood single‐cell RNA‐seq from leukaemic CTCL defined three malignant T‐cell programmes: MTC CM, MTC Reg and MTC E/EM, each with distinct features and candidate vulnerabilities. For example, inferred immune circuits highlighted actionable IL‐10/JAK–TYK2–STAT3 signalling, KIR–MHC I inhibitory interactions and myeloid/B‐cell inflammatory and ...
Beth A. Childs, Eslam A. Elghonaimy, Praveen Ramakrishnan Geethakumari, Kiran A. Kumar, Joseph F. Merola, Heather W. Goff, Todd A. Aguilera   +6 more
wiley   +1 more source

Hepatobiliary disorders associated with TNF-α inhibitors: a pharmacovigilance analysis of FAERS and JADER. [PDF]

Front Immunol
Chen H, Jiang S, Wang J, Zhang A, Zhu L.
europepmc   +1 more source

Genomic and proteomic insights into hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A dual pathogenic model of HS involving both epithelial dysfunction and systemic inflammation is supported. The HLA‐DRA association hints at autoimmune overlap, but the proteomic signature which is dominated by innate immune mediators favours an autoinflammatory classification, which may guide future therapeutic strategies and patient stratification ...
Maria Argyropoulou, Emmanouil Stylianakis, Isis Ricaño‐Ponce, Nick Keur, Theodora Kanni, Dimitra Stergianou, Mihai G. Netea, Vinod Kumar, Evangelos J. Giamarellos‐Bourboulis   +8 more
wiley   +1 more source

A rare case of community-acquired necrotizing pneumonia in a patient treated with adalimumab therapy. [PDF]

BMC Pulm Med
Ragunanthan B, Botrus B, Shrestha B, Kim J, Elsaghir H, Hollingshead C, Safi F.   +6 more
europepmc   +1 more source